As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.
Manufactured by PerkinElmer, a pioneer in immersion lens technologies, the Opera Phenix Plus provides a two-fold increase in image resolution.
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line. Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

The Évry shared-use Structural Biology Platform is a part of the Genopole-accredited Structure and Activity of Normal and Pathological Biomolecules Laboratory (SABNP: Inserm/University of Évry). In 2019, because of its recognized technologies and know-how in integrative structural biology, that platform was brought into the fold of the French Infrastructure for Integrated Structural Biology (FRISBI).
With the Opera Phenix Plus, the platform expands its possibilities for services and national & international partnerships.

Tens of thousands of high-resolution images in only a few hours

The Opera Phenix Plus HCS system can generate large quantities of images from biological samples in a matter of hours. Its high-resolution capacities enable the observation of defects in such cellular structures as the cytoskeleton, nucleoli, mitochondria, membrane proteins, neuron dendrites & axons and more. It can also be used for organoid studies or to observe fluorescent reporters for splicing, DNA repair, RNA translation and other cellular mechanisms of interest.
Furthermore, from the images it takes, the technology can produce exploitable quantitative data for high throughput drug screening. For example, the Opera Phenix Plus can produce 80,000 images in two hours for 150 pharmacological compounds.

HCS to energize MicroTubule bench

The HCS system will also provide impetus to MicroTubule bench (MTbench), another high-potential technology developed by SABNP and patented by Inserm Transfert. Producing as many as 63,000 images in only five hours, the Opera Phenix Plus greatly increases the number of images taken in a test run, thus greatly increasing in turn the reliability of this latter.

MTBench is a novel method for observing protein-protein and protein-RNA interactions, which are key phenomena in life sciences. The method detects and quantifies these phenomena in living cells via their naturally-present microtubule networks. MTBench will yield numerous applications, particularly for discovering and testing the actions of novel treatments and for expanding current knowledge on disease-associated cellular dysfunctions. For example, MTBench can be used in living cells to explore the impact of disease-causing mutations, better understand their underlying mechanisms and ultimately identify molecules able to counteract them.

CitationDavid Pastré, director of SABNP : «Thanks to the support of Genopole and the University of Évry, my lab was able to acquire an imaging technology combining high throughput and high resolution. The HCS system is vital to the development of our novel, patented technology for the analysis of biomolecular interactions, notably those involving RNA and proteins, in living cells. The equipment is mutualized and available to the entire public and private research community.»

How MTBench works
The microtubules (blue cylinders) are used as a support to capture and observe interaction phenomena. The “bait” protein (orange) is fused to a fluorescent reporter (red) and a microtubule binding domain. The “prey” protein (gray) is fused to another fluorescent reporter (green). Any interactions between bait and prey are visible and quantifiable via the fluorescence emitted along the microtubules.

How MTBench works
Interaction between bait and prey proteins on the microtubule surface underlying the MTBench technology.

HCS and MTBench: a duo to increase the attractiveness of the Structural Biology Platform

The complementarity of the high content screening system enables the large-scale and even industrial deployment of SABNP’s MTBench technology. In the setting of academic partnerships with other research labs, MTBench will be a part of the Structural Biology Platform’s service offer.

In the industrial setting, MTbench will be proposed by the Genopole company Synsight. With the stand-alone and MTBench-complementary advantages it brings, the Opera Phenix Plus system will make Synsight a major user of the Structural Biology Platform.

Illustration : Visualisation et quantification par la technologie MTBench des interactions protéines-protéines, observées à l’Opera Phenix+ dans une lignée cellulaire.

Visualisation et quantification par la technologie MTBench des interactions protéines-protéines, observées à l'Opera Phenix+ dans une lignée cellulaire.
La figure illustre un cas de forte interaction entre deux protéines, révélé par la fluorescence qui se concentre le long du réseau de microtubules.

Synsight is specialized in the discovery and design of novel therapeutic compounds for the pharmaceutical industry. The company’s activity is built upon a propriety and integrated platform that combines artificial intelligence (AI) and high content screening. Synsight proposes two complementary screening strategies: a phenotypic approach that evaluates therapeutic effect globally; and a therapeutic target-based approach that defines modes of action.

The first involves imaging analyses with deep-learning algorithms and will be made possible by the enormous amount of high-resolution images that Opera Phenix Plus will be able to produce (>50,000 daily). Synsight’s second approach involves biological targets, which the company seeks to modulate through high-throughput screening using the MTBench technology, for which it has exclusive commercial-use rights. Its approaches can be integrated within those of its clients, both for the identification (active compound identified by screening, called “hits”) and optimization (selection of high potential compounds, called “leads”) of drug candidates.

CitationCyril Bauvais, CEO of Synsight : «Synsight has an exclusive world license for the propriety cellular testing technology MTbench. When paired with extracellular biophysics tests, MTBench will provide multiparametric knowledge on molecular effects (within and without the cell) and enable artificial intelligence learning for the selection and design of efficacious compounds. In our opinion, the capacities of an AI can result only from the quality and robustness of the data underlying its learning. Quite simply, having access to such equipment is what will allow us to launch our offer.»

A scientific article there upon will soon be submitted in partnership with SABNP and the Institute of Natural Substances Chemistry (ICSN). Also, a cancer-associated interaction between two RNA binding proteins, YB-1 and Lin28, was recently published in Communications Biology (Nature) by Synsight, SABNP and Russian Academy of Sciences.

A unique platform in Europe

With the HCS Opera Phenix plus, the shared-use Structural Biology Platform gains a cutting-edge imaging technology. Associated with the novel MicroTubule bench method and under the team’s expert hand, the Opera Phenix plus will most notably create new possibilities for studies on protein-protein and protein-RNA interactions, which have great medical importance but suffer currently from a lack of technological means.

Pour aller plus loin

Access to the Structural Biology Platform

For more information on the platform, its technologies and the conditions for access to them, click here. Beyond the technologies discussed above, the Structural Biology Platform also provides access to a 600 MHz NMR spectrometer and two atomic force microscopes.

Article posted on 19 March 2021


Latest news

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

Logos Istem & Généthon

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.

IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

CNRGH - Consequences of phthalate exposure during pregnancy

Consequences of phthalate exposure during pregnancy

Jörg Tost and his team of the National Center of Human Genomics Research (CNRGH; CEA) were part of a large collaborative study aimed at determining the genome-wide correlation between phthalate exposure during pregnancy and methylation of placental DNA.

INtegrare / Généthon - Efficacité à long terme de la thérapie génique d’un déficit immunitaire

Long-term efficacy for an immunodeficiency gene therapy

A gene therapy conceived by Genethon has been shown to confer long-term efficacy against Wiskott-Aldrich syndrome, an immune deficiency disorder.

I-Stem, IPSEN & LMN recreate the human muscle-nerve system

A cellular model to recreate the human muscle-nerve system

Researchers from I-Stem, IPSEN and LMN have conceived a cellular muscle-nerve model to test the therapeutic potential of botulinum toxins in vitro.

Genoscope - CNS - Genopole's laboratory

Filling the gaps in the banana’s genome

Des chercheurs de Genoscope en collaboration avec une équipe du Cirad sont parvenus à reconstituer la séquence intégrale de chromosomes de bananier.

traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.


Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

muscle fiber

Signs of myopathy detected before muscle formation

An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself

Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

View all >
With the support from
Région île de France